Why are modified release dosage forms inappropriate to crush for enteral feeding tubes?

Why are modified release dosage forms inappropriate to crush for enteral feeding tubes?

• A. Crushing destroys their releasing properties; may cause overdose or death.
• B. They taste bitter.
• C. They are excreted unchanged.
• D. They are cheaper.

Answer: (A)

Crushing a modified-release product defeats the purpose of its design. These formulations are engineered to release the drug slowly, over time, or at a specific location in the GI tract. When you crush them, the release mechanism is destroyed and the entire dose can become available at once, causing a rapid rise in drug levels—dose dumping. This can lead to overdose or dangerous toxicity, which is especially risky for medicines with narrow therapeutic windows. In the context of enteral feeding tubes, this problem is even more concerning because the tube can alter absorption dynamics, but the core issue remains the loss of controlled release. The risk isn’t about taste, excretion, or cost; it’s about unleashing the full amount of drug at once instead of a steady, controlled release. Taste bitterness, excretion unchanged, and cost are not the primary safety concerns for modified-release forms given through enteral tubes.

Crushing a modified-release product defeats the purpose of its design. These formulations are engineered to release the drug slowly, over time, or at a specific location in the GI tract. When you crush them, the release mechanism is destroyed and the entire dose can become available at once, causing a rapid rise in drug levels—dose dumping. This can lead to overdose or dangerous toxicity, which is especially risky for medicines with narrow therapeutic windows.

In the context of enteral feeding tubes, this problem is even more concerning because the tube can alter absorption dynamics, but the core issue remains the loss of controlled release. The risk isn’t about taste, excretion, or cost; it’s about unleashing the full amount of drug at once instead of a steady, controlled release.

Taste bitterness, excretion unchanged, and cost are not the primary safety concerns for modified-release forms given through enteral tubes.